<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927260</url>
  </required_header>
  <id_info>
    <org_study_id>AVIATOR2020</org_study_id>
    <nct_id>NCT04927260</nct_id>
  </id_info>
  <brief_title>French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients Treated With Avapritinib</brief_title>
  <acronym>AVIATOR2020</acronym>
  <official_title>French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients Treated With Avapritinib : AVapritinib Real-life observatTORy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blueprint Medicines Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      GIST are rare mesenchymal tumors of the gastrointestinal tract characterized by somatic&#xD;
      mutations in the gene encoding the KIT (85%) or the PDGFRα (8%) protein. Treatment of&#xD;
      localized forms relies on adequate surgery without tumor spillage and sometimes systemic&#xD;
      treatment with imatinib according to risk of relapse defined by localization, tumor size and&#xD;
      mitotic count, as well as mutational status. More than 40% of cases may recur and&#xD;
      metastasize. Advanced and relapsing forms are currently treated with oral tyrosine-kinase&#xD;
      inhibitors (TKI) of KIT and PDGFR such as imatinib (standard treatment), sunitinib (2nd line)&#xD;
      and regorafenib (3rd line). Nevertheless, imatinib has little or no activity in patients&#xD;
      harboring the D842V mutation in the exon 18 of PDGFRα (20% of gastric GIST, 6% of all GIST&#xD;
      patients). Consequently, other therapeutic alternatives are needed.&#xD;
&#xD;
      Results from the phase I single-arm NAVIGATOR study show that avapritinib has significant&#xD;
      efficacy in GIST patients with PDGFRα D842V mutation (ORR = 86 %). In France, an&#xD;
      authorization for temporary use (ATUc) starting on September 21st, 2020 has been granted by&#xD;
      the National Agency for Safety of Medicines and Health Products (ANSM). It allows the early&#xD;
      availability of avapritinib in France while waiting for Market Authorization Approval (AMM).&#xD;
      This ATUc will be accompanied by a protocol of therapeutic use and collection of information&#xD;
      (PUT) that describes the frequency of patient visits.&#xD;
&#xD;
      The objective of this real-life registry is to perform a long-term longitudinal follow up of&#xD;
      PDGFRA D842V-mutated GIST patients treated with avapritinib and to collect effectiveness and&#xD;
      safety data. It will be implemented in parallel to the ATUc until June 2023.&#xD;
&#xD;
      Data from the electronic health record (EHR) will be collected. Moreover, as per the ANSM's&#xD;
      requirements, quality of life and cognitive function will be investigated using FACT-G,&#xD;
      FACT-Cog and MoCA questionnaires.&#xD;
&#xD;
      Undesirable effects will be collected as well. Follow-up is envisioned for a minimum of 2&#xD;
      years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>up to 48 months</time_frame>
    <description>survival of patients treated with Avapritinib in real life according to overall survival.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>after 12, 24 and 36 months</time_frame>
    <description>according to RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of long-term responders</measure>
    <time_frame>up to 48 months</time_frame>
    <description>(&gt;24 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment</measure>
    <time_frame>up to 48 months</time_frame>
    <description>duration in months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Nature of AEs</measure>
    <time_frame>up to 48 months</time_frame>
    <description>AEs graded using Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety : Frequency of AEs</measure>
    <time_frame>up to 48 months</time_frame>
    <description>AEs graded using Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety : Severity of AEs</measure>
    <time_frame>up to 48 months</time_frame>
    <description>AEs graded using Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive impairment in real-life according to MoCA questionnaires</measure>
    <time_frame>Day 1, Day 15, Month 2, Month 3, Month 6, Month 12, Month 18, Month 24, Month 36</time_frame>
    <description>Montreal Cognitive Assessment (MoCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive impairment in real-life according to FACT-Cog</measure>
    <time_frame>Day 1, Day 15, Month 2, Month 3, Month 6, Month 12, Month 18, Month 24, Month 36</time_frame>
    <description>Functional Assessment of Cancer Therapy - Cognitive Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life in real-life according to FACT-G questionnaire</measure>
    <time_frame>Day 1, Day 15, Month 2, Month 3, Month 6, Month 12, Month 18, Month 24, Month 36</time_frame>
    <description>Functional Assessment of Cancer Therapy - General</description>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>GIST</condition>
  <condition>GIST, Malignant</condition>
  <condition>PDGFR-Alpha D842V</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patient treated by Avapritinib in real life</intervention_name>
    <description>The patients included are treated with Avapritinib as part of their care. There is no change in treatment associated with this study.&#xD;
Patients must regularly complete various questionnaires: FACT-G, FACT-COG, and a neuropsychiatrist or a trained physician will give them the MoCA.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with GIST harboring a PDGFRa D842V mutation and treated with Avapritnib can be&#xD;
        included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  I1. Adult (≥18 years old), male or female&#xD;
&#xD;
          -  I2. Patient with a histologically or cytologically-confirmed diagnosis of unresectable&#xD;
             or metastatic GIST harboring the D842V mutation in the PDGFRα gene&#xD;
&#xD;
          -  I3. Patient treated with Avapritinib&#xD;
&#xD;
          -  I4. Non opposition to the use of her/his data&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  E1. Patient not meeting all the inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MEHDI BRAHMI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien Bollard</last_name>
    <phone>04 78 78 28 28</phone>
    <email>julien.bollard@lyon.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra BIETTE</last_name>
    <phone>04 78 78 28 28</phone>
    <email>alexandra.biette@lyon.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>LOIC CHAIGNEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>ELSA KALBACHER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>GUILLAUME MEYNARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Insitut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MAUD TOULMONDE</last_name>
    </contact>
    <investigator>
      <last_name>MAUD TOULMONDE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin BOURCIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie COUSIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Geroges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alice HERVIEU</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle DESMOULINS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Bollard</last_name>
    </contact>
    <investigator>
      <last_name>Mehdi BRAHMI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Olivier BOUCHE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oliver MIR</last_name>
    </contact>
    <investigator>
      <last_name>Olivier MIR</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Axel LE CESNE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin VERRET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rastilav BAHLEDA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

